From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
CAS Number
PubChem CID
Chemical and physical data
Formula C13H19NO2
Molar mass 221.30 g/mol
3D model (JSmol)

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]


  1. ^ Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107. 
  2. ^ Waldmeier PC, Maître L, Baumann PA, et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology. 130 (1-2): 1–10. doi:10.1016/0014-2999(86)90177-9. PMID 2877890. 
  3. ^ a b c Delini-Stula A, Fischbach R, Gauthier JM, et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology. 2 (3): 201–15. doi:10.1097/00004850-198707000-00003. PMID 3320185.